Modality
siRNA
MOA
EGFRi
Target
GLP-1R
Pathway
DDR
Endometrial CaMMHuntington's
Development Pipeline
Preclinical
~Nov 2012
→ ~Feb 2014
Phase 1
~May 2014
→ ~Aug 2015
Phase 2
~Nov 2015
→ ~Feb 2017
Phase 3
~May 2017
→ ~Aug 2018
NDA/BLA
~Nov 2018
→ ~Feb 2020
Approved
May 2020
→ Apr 2030
ApprovedCurrent
NCT08596646
2,508 pts·Endometrial Ca
2021-08→TBD·Terminated
NCT08080195
1,871 pts·MM
2021-10→2029-10·Active
NCT07954451
404 pts·Endometrial Ca
2020-05→2030-04·Not yet recruiting
4,783 total pts2 indications
CompletedCurrentUpcoming
Catalysts (2)
2029-10-063.5y awayPh3 Readout· MM
2030-04-014.0y awayPh3 Readout· Endometrial Ca
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Approved
Not yet…
Approved
Termina…
Approved
Active
Catalysts
Ph3 Readout
2029-10-06 · 3.5y away
MM
Ph3 Readout
2030-04-01 · 4.0y away
Endometrial Ca
ActiveTerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08596646 | Approved | Endometrial Ca | Terminated | 2508 | HAM-D |
| NCT08080195 | Approved | MM | Active | 1871 | eGFR |
| NCT07954451 | Approved | Endometrial Ca | Not yet recr... | 404 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Mavuglumide | Bayer | Approved | GLP-1R |